Phase 3 clinical trial

This registry will gather real-world safety and effectiveness data on infliximab in Chinese children with moderate-to-severe Crohn's disease, which can help clinicians and families understand how the drug performs...

The trial suggests starting infliximab early can delay the need for further biologic escalation in children with moderate-to-severe Crohn’s disease, and that stopping anti‑TNF after induction often leads to relapse.

If confirmed, starting effective biologic therapy at diagnosis could lower the chance of surgery and complications over several years for people with moderate-to-severe Crohn’s disease.

Hospitalized patients with acute severe ulcerative colitis face high risks of colectomy and steroid-related harms. This trial tests whether an oral JAK1 inhibitor (upadacitinib) started in hospital can avoid steroids,...

This post‑marketing study will add safety and real‑world effectiveness information about Tabellvi® (adalimumab) in Chinese adults with moderate to severe Crohn's disease, which can inform patients and clinicians using or...

The study suggests starting anti-TNF therapy with an immunomodulator at diagnosis may reduce surgery, hospital stays, and progression to complicated Crohn’s over 5 years — outcomes that matter to patients and clinicians...

This trial tests whether starting with one biologic or targeted therapy versus another (and the sequence of switches) affects remission, safety, and quality of life for people with moderate-to-severe ulcerative colitis —...

Long-term safety information matters for people with ulcerative colitis considering or already taking filgotinib, because LTE studies track adverse events and lab changes over years. Findings from such a study can...

The 5-year PROFILE follow-up is presented as strong evidence that early, effective therapy (in this case infliximab plus an immunomodulator) can change the long-term course of Crohn’s disease by lowering surgery rates...

If confirmed, starting anti‑TNF therapy (infliximab) early plus an immunomodulator may reduce surgeries, hospital admissions, and progression to complicated disease behavior over 5 years compared with a traditional...

This trial is testing risankizumab in children with moderate-to-severe Crohn’s disease to learn how the drug behaves in kids, whether it’s safe, and whether it reduces disease activity — information that could expand...

Trials testing intestinal ultrasound–guided treat-to-target strategies and late-stage therapies could change how Crohn’s disease is monitored and treated if they show improved outcomes.

Phase 3 trials test whether a new oral therapy can induce remission in people with moderate-to-severe ulcerative colitis who have not responded to or cannot tolerate existing treatments. If positive, results could add...

Knowing which treatment target (symptom control alone versus adding endoscopic and histological remission) leads to better long-term outcomes could change how aggressively clinicians treat ulcerative colitis and what...

This trial studies adalimumab safety and pediatric dosing in children with moderate–severe Crohn's disease, which is directly relevant to families and clinicians considering anti-TNF therapy for pediatric IBD.

Phase 3 trials test whether a new drug is effective and safe enough to be considered for clinical use. ABX464 is being evaluated as a potential new oral treatment for people with moderate-to-severe ulcerative colitis who...

This trial describes a large Phase 3 extension study collecting long-term safety and tolerability data for tulisokibart (MK-7240), an investigational TL1A-targeting antibody for Crohn’s disease and ulcerative colitis....

Clinical trials test new treatments that could become options for people with moderate to severe Crohn’s disease. This sponsor-supported notice also highlights the need for broader representation in research, which...

Long-term, real-world safety data help patients and clinicians understand risks — especially serious infections — when a newer ulcerative colitis drug is used in routine practice. This registry entry shows Pfizer is...

Anti‑TL1A drugs represent a new mechanism with phase 2 signals for clinical remission and endoscopic response in both UC and Crohn's disease, plus early biomarker evidence suggesting antifibrotic effects—areas directly...

This study tests a common clinical question: whether increasing vedolizumab frequency helps patients who show no endoscopic response after 6 months. The results suggest intensification raised drug levels but did not...

This study will gather real‑world effectiveness and patient‑reported outcome data for guselkumab in adults with moderate‑to‑severe Crohn’s disease or ulcerative colitis, which may help clinicians and patients understand...

Patients and clinicians considering guselkumab for Crohn’s disease or ulcerative colitis may gain real-world evidence on how the drug performs across treatment lines and subgroups over up to 96 weeks. The study will...

Phase 3 testing of guselkumab (an IL-23–targeting biologic) in moderately to severely active ulcerative colitis could expand treatment options if the trial meets its endpoints and shows an acceptable safety profile. The...

A subcutaneous induction option could make starting risankizumab easier and less burdensome than IV infusions for many people with Crohn's disease, potentially expanding access and convenience.

This trial tests whether an oral S1P modulator (etrasimod) is more effective than standard mesalazine for inducing remission in adults with active UC — a question that could affect initial treatment choices in China.

Perianal fistulas are a serious, common complication of Crohn's disease that are often difficult to heal. This study tests a real-world combination of surgery plus an approved IL-23 inhibitor (mirikizumab) to see if...

Researchers are testing whether targeting fungi with fluconazole can boost how well IL-23 biologics work for Crohn’s disease — if positive, this could point to a new adjunctive strategy to improve responses to biologic...

Pouchitis is a common, sometimes chronic complication after IPAA surgery for ulcerative colitis and can substantially affect quality of life. If topical 5-ASA prevents pouchitis, it could offer a simple prophylactic...

This analysis suggests upadacitinib works and has a similar safety and pharmacokinetic profile in East Asian patients with moderately to severely active ulcerative colitis as in the global trials, which may reassure...

A new Phase 3 trial is testing ponesimod, an oral S1P-modulator, for moderately to severely active ulcerative colitis — this could expand oral treatment options if later shown effective and safe.

Many people with IBD experience persistent fatigue, pain and faecal incontinence even when inflammation is controlled; this programme tested a supported online self-management approach to help those symptoms and assessed...

Patients and clinicians are interested in whether combining two targeted biologic therapies can induce stronger endoscopic healing for people with difficult-to-treat Crohn's disease, and whether benefit can be maintained...

A new pediatric Phase 3 trial of filgotinib could broaden approved treatment choices for children and teens with moderate-to-severe ulcerative colitis, especially for those who have not responded to or cannot tolerate...

Researchers are testing whether short-term dual therapy with vedolizumab plus tofacitinib can induce remission in people with moderate–severe UC who have failed prior TNF blockers. If effective and safe, this approach...

Long-term extension trials help show whether a drug’s benefits and safety persist over time. For people with Crohn’s disease, this study focuses on maintaining endoscopic improvement and clinical remission with...

The trial tests two low-cost adjuncts — a Lactobacillus probiotic and a multi–trace-element supplement — added to biologic-based standard care to see if they help maintain remission in ulcerative colitis. If effective,...

Faecal microbiota transfer is being tested in a large Phase 3 trial as a possible new treatment approach for active ulcerative colitis, and this study also looks at safety and how the therapy changes the gut microbiome...

Mirikizumab is being tested specifically in children with moderate-to-severe Crohn’s disease; successful results could expand treatment options for pediatric IBD. The study measures both symptom-based and endoscopic...

This trial is testing whether continued mirikizumab treatment helps children and teens with ulcerative colitis or Crohn’s disease achieve and maintain remission over the long term. Results could expand pediatric...

A structured ERP adapted for children could shorten hospital stays and improve recovery after pediatric GI surgery; this trial tested both clinical effectiveness and real-world implementation across many pediatric...

People with IBD who have no or few symptoms but still have moderate–severe inflammation on endoscopy face uncertainty about whether to switch therapies to aim for endoscopic remission.

Researchers and clinicians are increasingly studying combinations of IBD drugs because single‑drug remission rates have plateaued; dual therapy may improve outcomes for patients who have failed prior treatments.

This trial directly informs a common clinical question: whether patients in deep remission can safely stop anti‑TNF therapy. Results show higher relapse risk after withdrawal, but many patients can be successfully...

People with Crohn’s disease who are overweight or have obesity may have different disease and treatment needs. This Phase 3 trial is testing whether adding tirzepatide to mirikizumab improves both disease outcomes and...

Real‑world studies of ustekinumab help patients and clinicians understand how the drug performs outside clinical trials, including effectiveness for steroid‑free remission and use across different UK care settings.

The study tests mirikizumab in routine clinical practice against standard biologic therapies to see if it lowers healthcare needs and improves symptoms and quality of life for people with Crohn’s disease or ulcerative...

A Phase 3 study is testing whether oral tofacitinib can induce and maintain remission in children with moderate-to-severe ulcerative colitis — a key step before pediatric regulatory approvals and wider clinical use.